Treatment options for localized prostate cancer.

In the United States, more than 90 percent of prostate cancers are detected by serum prostate-specific antigen testing. Most patients are found to have localized prostate cancer, and most of these patients undergo surgery or radiotherapy. However, many patients have low-risk cancer and can follow an active surveillance protocol instead of undergoing invasive treatments. Active surveillance is a new concept in which low-risk patients are closely followed and proceed to intervention only if their cancer progresses. Clinical guidelines can help in selecting between treatment or active surveillance based on the cancer's stage and grade, the patient's prostate-specific antigen level, and the comorbidity-adjusted life expectancy. Radical prostatectomy or external beam radiation therapy is recommended for higher-risk patients. These treatments are almost equivalent in effectiveness, but have different adverse effect profiles. Brachytherapy is an option for low- and moderate-risk patients. Evidence is insufficient to determine whether laparoscopic or robotic surgery or cryotherapy is superior to open radical prostatectomy.

[1]  P. Schellhammer,et al.  Development of a scale to assess patient misperceptions about treatment choices for localized prostate cancer , 2010, BJU international.

[2]  Susanne Hempel,et al.  Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. , 2006, The Journal of urology.

[3]  A. Potosky,et al.  Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA , 2005, BMC Cancer.

[4]  P. Schellhammer,et al.  Patients’ Survival Expectations before Localized Prostate Cancer Treatment by Treatment Status , 2009, The Journal of the American Board of Family Medicine.

[5]  T. Tammela,et al.  Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. , 2009, European urology.

[6]  V. Shavers,et al.  Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer , 2004, Journal of General Internal Medicine.

[7]  Matthew R Cooperberg,et al.  Contemporary trends in low risk prostate cancer: risk assessment and treatment. , 2007, The Journal of urology.

[8]  A. Zietman,et al.  Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. , 2000, JAMA.

[9]  E. Steyerberg,et al.  Anxiety and distress during active surveillance for early prostate cancer , 2009, Cancer.

[10]  L. Klotz Active surveillance for prostate cancer: for whom? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Carroll,et al.  20-year outcomes following conservative management of clinically localized prostate cancer , 2005 .

[12]  L. Ferrucci,et al.  Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. , 2006, Journal of the National Cancer Institute.

[13]  Nicky Britten,et al.  Who decides about prostate cancer treatment? A qualitative study. , 2003, Family practice.

[14]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[15]  Hans Garmo,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The New England journal of medicine.

[16]  D. Dearnaley,et al.  A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival , 2006, British Journal of Cancer.

[17]  John T. Wei,et al.  Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. , 2006, Journal of the National Cancer Institute.

[18]  Pär Stattin,et al.  Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study , 2010, Journal of the National Cancer Institute.

[19]  M. Janssen-Heijnen,et al.  The independent prognostic value of comorbidity among men aged < 75 years with localized prostate cancer: a population‐based study , 2001, BJU international.

[20]  G. Murphy,et al.  American Cancer Society guideline for the early detection of prostate cancer: Update 1997 , 1997, CA: a cancer journal for clinicians.

[21]  A. D'Amico,et al.  American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.

[22]  M. Cooperberg,et al.  Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. , 2003, The Journal of urology.